



DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)

NEWS RELEASE:

DIGITAL LIFE LINE PTE. LTD. ANNOUNCES THE CLINICAL DEPLOYMENT OF AUTOMATED VISUAL ACUITY TEST DEVICES AT A HOSPITAL OPHTHALMOLOGY CLINIC IN HONG KONG

SINGAPORE – 5 March 2025 — DISA Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”), is excited to share another clinical deployment update by Digital Life Line Pte. Ltd. (“**DLL**”), a subsidiary of DiSa Digital Safety Pte. Ltd. that is a wholly-owned subsidiary of the Company. DLL is thrilled to announce that its Automated Visual Acuity Test device (“**AVAT**”) has now been approved for clinical deployment at a hospital ophthalmology clinic in Hong Kong to offer visual acuity testing after a successful 3-month trial deployment at a public ophthalmology clinic in Hong Kong.

With myopia expected to affect nearly half of the world’s population by 2050, particularly in East Asia, Hong Kong stands out as one of the regions with the highest prevalence of myopia, affecting more than 40% of school children at the age of eight¹. The deployment of AVAT for visual acuity testing, one of the most common eye examinations, is expected to help alleviate the burden on ophthalmology clinics by optimising both manpower and space resources.

AVAT is the result of years of dedicated research and development work by the Department of Ophthalmology at the National University Hospital (“**NUH**”) and Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore (“**NUS Medicine**”) to alleviate operational challenges with visual acuity testing.

Associate Professor Victor Koh, Head, Department of Ophthalmology at NUH and NUS Medicine shared, “AVAT is designed to automate a commonly-performed visual test with less direct supervision from clinic staff. This frees up manpower to perform other tasks to improve productivity in clinics with high patient load.”

DLL has completed the notification to Health Science Authority of Singapore in August 2023, officially classifying AVAT as a Class A medical device. Since then, AVAT has been used to conduct automated visual acuity tests for over 2,000 patients in hospitals, schools and community settings. The device has shown excellent correlation with standard testing methods, while seemingly outperforming similar devices in terms of manpower and space efficiency.

“The clinical deployment of AVAT in Hong Kong represents a significant milestone for DLL as we expand our innovations globally, enhancing the accessibility and convenience of accurate vision screening through automation and Artificial Intelligence. We will continue collaborating with both public and private eye centers to offer AVAT and are committed to developing more portable, user-friendly digital vision screening devices for both tertiary and primary care.” **said Mr. Eddie Chng, the Managing Director and Chief Executive Officer of DLL and the Company.**

¹ <https://www.med.cuhk.edu.hk/press-releases/cuhk-study-demonstrates-a-2-5-fold-increase-in-myopia-incidence-in-children-during-covid-19-pandemic-due-to-less-time-outdoors-and-more-time-on-screens>

-----End-----

About DISA Limited (SGX Code - 532.SI / Bloomberg - DISA:SP / Reuters - DISA.SI)

DISA Limited, is a publicly traded company on the Singapore Catalist Stock Exchange. Along with its subsidiaries, the Group is dedicated to pioneering and adopting cutting-edge technologies that enhance outcomes, reduce costs, and improve efficiencies in the healthcare and consumer industries.

Bringing scaled solutions that thrive in a changing world, we leverage on our strong in-house R&D capabilities to continuously pursue new innovations and disruptive technology (such as Artificial Intelligence, Internet of Things, etc.) for the digitalisation of products and services that optimises efficiency and quality standards in our targeted markets.

More information is available at www.disa.sg.

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms. Lee Khai Yinn, Registered Professional, SAC Capital Private Limited.

Address: 1 Robinson Road, #21-01 AIA Tower, Singapore 048542

Telephone number: +65 6232 3210